Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab

Gastroenterology. 2020 Aug;159(2):784-787. doi: 10.1053/j.gastro.2020.03.073. Epub 2020 Apr 8.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab / adverse effects
  • Adalimumab / immunology*
  • Antibodies, Anti-Idiotypic / blood*
  • Crohn Disease / blood
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology
  • Epitopes
  • HLA-DQ alpha-Chains / genetics*
  • HLA-DQ alpha-Chains / immunology
  • Haplotypes*
  • Humans
  • Infliximab / adverse effects
  • Infliximab / immunology*
  • Polymorphism, Genetic*
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / adverse effects
  • Tumor Necrosis Factor Inhibitors / immunology*

Substances

  • Antibodies, Anti-Idiotypic
  • Epitopes
  • HLA-DQ alpha-Chains
  • HLA-DQA1 antigen
  • Tumor Necrosis Factor Inhibitors
  • Infliximab
  • Adalimumab